Is the Future of Statins Aligned with New Novel Lipid Modulation Therapies?

Dyslipidemia is an established risk factor for the development of atherosclerotic cardiovascular disease. Statin therapy has been proven in a number of clinical trials to lower the risk of acute cardiovascular events and is the mainstay of cholesterol treatment. Despite current optimal treatment for...

Full description

Saved in:
Bibliographic Details
Published in:Current atherosclerosis reports 2013-02, Vol.15 (2), p.300-300, Article 300
Main Authors: Phan, Binh An P., Toth, Peter P.
Format: Article
Language:English
Subjects:
Angiology
Atherosclerosis - epidemiology
Atherosclerosis - etiology
Atherosclerosis - prevention & control
Cardiology
Clinical Trials as Topic - methods
Dyslipidemias - blood
Dyslipidemias - complications
Dyslipidemias - epidemiology
Global Health
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Incidence
Lipids - blood
Medicine
Medicine & Public Health
Risk Factors
Section Editor
Statin Drugs (MB Clearfield
Topical Collection on Statin Drugs
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dyslipidemia is an established risk factor for the development of atherosclerotic cardiovascular disease. Statin therapy has been proven in a number of clinical trials to lower the risk of acute cardiovascular events and is the mainstay of cholesterol treatment. Despite current optimal treatment for dyslipidemia, many patients fail to reach adequate cholesterol treatment goals and remain at a significantly increased risk of cardiovascular events. Given this residual risk, there is a critical need for additional lipid therapies that could augment the ability of statins to lower the burden of atherogenic lipoproteins and, in some cases, raise levels of high-density lipoproteins. A number of novel lipid-altering therapies have been developed and are currently in clinical trials. In this review, we discuss these promising therapies, which include PCSK9 inhibitors, apolipoprotein B antisense oligonucleotides, microsomal transfer protein inhibitors, thyroid mimetics, and cholesteryl ester transfer protein inhibitors. Although statin therapy is the current recommended primary treatment for dyslipidemia, emerging novel agents may become adjuvant therapies in the treatment of atherosclerotic heart disease.
ISSN:1523-3804
1534-6242
DOI:10.1007/s11883-012-0300-x